J
James D. Young
Researcher at University of Alberta
Publications - 241
Citations - 16156
James D. Young is an academic researcher from University of Alberta. The author has contributed to research in topics: Nucleoside & Nucleoside transporter. The author has an hindex of 63, co-authored 240 publications receiving 15574 citations. Previous affiliations of James D. Young include Cornell University & Cross Cancer Institute.
Papers
More filters
Journal ArticleDOI
Global Mapping of the Yeast Genetic Interaction Network
Amy Hin Yan Tong,Guillaume Lesage,Gary D. Bader,Huiming Ding,Hong Xu,Xiaofeng Xin,James D. Young,Gabriel F. Berriz,Renee L. Brost,Michael Chang,Yiqun Chen,Xin Cheng,Gordon Chua,Helena Friesen,Debra S. Goldberg,Jennifer Haynes,Christine Humphries,Grace He,Shamiza Hussein,Lizhu Ke,Nevan J. Krogan,Zhijian Li,Joshua N. Levinson,Hong Lu,Patrice Menard,Christella Munyana,Ainslie B. Parsons,Owen Ryan,Raffi Tonikian,Tania Michelle Roberts,Anne-Marie Sdicu,Jesse Shapiro,Bilal N. Sheikh,Bernhard Suter,Sharyl L. Wong,Lan V. Zhang,Hongwei Zhu,Christopher G. Burd,Sean Munro,Chris Sander,Jasper Rine,Jack Greenblatt,Matthias Peter,Anthony Bretscher,Graham Bell,Frederick P. Roth,Grant W. Brown,Brenda J. Andrews,Howard Bussey,Charles Boone +49 more
TL;DR: Because digenic interactions are common in yeast, similar networks may underlie the complex genetics associated with inherited phenotypes in other organisms.
Journal ArticleDOI
The equilibrative nucleoside transporter family, SLC29.
TL;DR: The human SLC29 family of proteins contains four members, designated equilibrative nucleoside transporters (ENTs) because of the properties of the first-characterised family member, hENT1, which possess similar broad substrate specificities for purine and pyrimidine nucleosides, but hENT2 in addition efficiently transports nucleobases.
Journal Article
Functional Nucleoside Transporters Are Required for Gemcitabine Influx and Manifestation of Toxicity in Cancer Cell Lines
John R. Mackey,Rajam S. Mani,Milada Selner,Delores Mowles,James D. Young,Judith A. Belt,Charles R. Crawford,Carol E. Cass +7 more
TL;DR: The data suggested that the type of NT activities possessed by a cell may be an important determinant of its sensitivity to gem citabine and that NT deficiency may confer significant gemcitabine resistance.
Journal ArticleDOI
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs
Mark Griffiths,Nick Beaumont,Sylvia Y.M. Yao,Manickavasagam Sundaram,Christine E. Boumah,Anthony Davies,Anthony Davies,Francis Y. P. Kwong,Imogen Coe,Carol E. Cass,James D. Young,Stephen A. Baldwin +11 more
TL;DR: The isolation of a human placental cDNA encoding a 456-residue glycoprotein with functional characteristics typical of an es-type transporter is reported, predicted to possess 11 membrane-spanning regions and is homologous to several proteins of unknown function in yeast, nematodes, plants and mammals.
Journal ArticleDOI
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Jennifer L. Spratlin,Randeep Sangha,Darryl D. Glubrecht,Laith Dabbagh,James D. Young,Charles Dumontet,Carol E. Cass,Raymond Lai,John R. Mackey +8 more
TL;DR: Immunohistochemistry for hENT1 shows promise as a molecular predictive assay to appropriately select patients for palliative gemcitabine chemotherapy but requires formal validation in prospective, randomized trials.